Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries

Abstract

BackgroundThere have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recommendations, we undertook a survey across a range of organisations engaged with hepatitis testing in low- and middle-income countries (LMICs). Our objective was to describe current hepatitis B and C testing practices across a range of settings in different countries, as well as key barriers or challenges encountered and proposed solutions to promote testing scale-up.MethodsHepatitis testing programmes in predominantly LMICs were identified from the WHO Global Hepatitis Programme contacts database and through WHO regional offices, and invited to participate. The survey comprised a six-part structured questionnaire: general programme information, description of hepatitis testing, treatment and care services, budget and funding, data on programme outcomes, and perceptions on key barriers encountered and strategies to address these.ResultsWe interviewed 22 viral hepatitis testing programmes from 19 different countries. Nine were from the African region; 6 from the Western Pacific; 4 from South-East Asia; and 3 from Eastern Europe. All but four of the programmes were based in LMICs, and 10 (45.5%) were supported by non-governmental or international organizations. All but two programmes undertook targeted testing of specific affected populations such as people living with HIV, people who inject drugs, sex workers, health care workers, and pregnant women. Only two programmes focussed on routine testing in the general population. The majority of programmes were testing in hospital-based or other health facilities, particularly HIV clinics, and community-based testing was limited. Nucleic acid testing (NAT) for confirmation of HCV and HBV viraemia was available in only 30% and 18% of programmes, respectively. Around a third of programmes required some patient co-payment for diagnosis. The most commonly identified challenges in scale-up of hepatitis testing were: limited community awareness about viral hepatitis; lack of facilities or services for hepatitis testing; no access to low cost treatment, particularly for HCV; absence of national guidance and policies; no dedicated budget for hepatitis; and lack of trained health care and laboratory workers.ConclusionsAt this early stage in the global scale-up of testing for viral hepatitis, there is a wide variation in testing practices and approaches across different programmes. There remains limited access to NAT to confirm viraemia, and patient self-payment for testing and treatment is common. There was consensus from implementing organizations that scale-up of testing will require increased community awareness, health care worker training, development of national strategies and guidelines, and improved access to low cost NAT virological testing.Electronic supplementary materialThe online ver...

Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study

“…While affordable in comparison to NAT, antibody testing has been demonstrated to generate false positive results in 10% of tests, especially within low prevalence populations and has limited clinical utility among patients who have cleared spontaneously or from previous treatment . Furthermore, in a programmatic review by Ishizaki et al, within LMIC settings, 50% of programs utilized a standalone antibody rapid test for diagnosis, and only a third of programs offered confirmation RNA testing with 30% of these requiring a patient co‐payment . The review also highlighted concerns over test accuracy and quality assurance.…”

Hepatitis C: Is eradication possible?

“…Screening programmes are commonly supported by non‐governmental or international organizations and they usually test specific populations and only marginally perform routine testing in the general population. Moreover, testing is principally hospital‐based …”

“…Direct-acting antiviral agents are an extraordinary tool to curb the burden of HCV infection, but the simple availability of these drugs is not sufficient to obtain a real impact on morbidity and mortality, Moreover, testing is principally hospital-based. 18 To identify infected people who are unaware of their status, efforts must be made in two main directions: access to test must be expanded and easier and faster instruments to determine HCV status must be provided. In high-income countries, testing of specific highrisk populations must be maintained and increased.…”

Using a Hepatitis B surveillance system evaluation in Fujian, Hainan, and Gansu Provinces to improve data quality and assess program effectiveness, China, 2015

“…Lack of awareness among health care workers and laboratory staff was also identi ed as a major gap in viral hepatitis case detection and reporting in a survey on HBV and HCV testing and service delivery in low and middle-income countries [28]. Sta ng constraints and doctor-to-patient ratios could also affect the correct case classi cation and reporting [29,30]. Targeting lower-level hospital staff with speci c interventions, including site visits and regular reviews, may increase the reporting accuracy.…”